NEW YORK (GenomeWeb News) – Pfizer has tapped Cellartis to help it develop an in vitro screening model for predicting toxicity of new chemical entities in humans.
 
Cellartis said Tuesday that the collaboration gives Pfizer access to its human Embryonic Stem cell technology to develop the screening system, for which Cellartis will receive an upfront fee and research funding, and it will hold the rights to sub-license, use, and sell the toxicity screening model.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.

Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, Phys.org says.

In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.

China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.